Rozanolixizumab
ATC L04AL02 · 8 markets · 20 records
Rozanolixizumab
Forms
US 4 records · 1 strengths
- 140 mginjectionRYSTIGGO
CA 4 records · 1 strengths
- 140 mg/1 mLliquidRYSTIGGO
GB 3 records · 3 strengths
- 280 mg/2 mLinjectionRystiggo 280mg/2ml solution for injection vials
- 560 mg/4 mLinjectionRystiggo 280mg/2ml solution for injection vials
- 420 mg/3 mLinjectionRystiggo 280mg/2ml solution for injection vials
AU 3 records · 3 strengths
- 280 mg/2 mLinjectionRYSTIGGO
- 140 mg/mLinjectionRYSTIGGO rozanolixizumab 140 mg/mL solution for injection for infusion vial
Records without a stated strength · 1 RYSTIGGO
HK 3 records · 1 strengths
Records without a stated strength · 1 RYSTIGGO SOLUTION FOR INJECTION 280MG/2ML
ES 1 records · 1 strengths
- 140 mg/1 mLinjectionRYSTIGGO
TW 1 records · 1 strengths
- 140 mginjectionRystiggo solution for injection 140 mg/ml肌挺力注射液劑140毫克/毫升
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 RYSTIGGO
The same ingredient can carry completely different
brand names in different countries, and the same name can point to a different ingredient.
Listed by country — not interchangeable.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.
A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.